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Conclusion: Administration of an additional HB is feasible, 
safe and well tolerated in terms of acute and short-term late 
skin and subcutaneous toxicity even though it seems to have 
a role in the edema occurrence. Although G2 dermatitis 
occurred in 16.47% of pts receiving HB vs 7.04% not receiving 
it, the difference was not significant, probably due to few 
observed events. Long term follow up data and a larger 
sample size are needed to confirm these data, assess late 
toxicity and clinical outcomes. 
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Purpose or Objective: The aim of this study was to compare 
the volumes obtained with surgical clips during breast 
conserving surgery of breast cancer patients with volume 
determined using FDG positive tumor volumes outlined in 
pre-operative PET-CT imaging and find out the deviations 
that arise. 
 
Material and Methods: For initial diagnostic PET-CT 
requested by the surgeon, the patients were positioned on 
the breast board with the arm on the ipsilateral side up. 
Those without metastatic tumors and applicable for breast 
conserving surgery went under operation in compliance with 
oncoplastic surgery principles. 4 clips were placed at the 
tumor lodge. For 15 of the patients, before continuing with 
further therapy, the tumor volume outlined with the surgical 
clips and that contoured using the area with FDG affinity 
viewed on the PET-CT were determined. Results were 
statistically analyzed with SPSS software. 
 
Results: This study determined that methods used in 
oncoplastic surgery (such as flap shifting) resulted in 
displacements of the tumors from their original locations. For 
statistics we apply paired t test to the results that we have 
from these different techniques and found the values 
respectively for x,y,z as 0.929, 0.119, 0.991. Even the p 
value that we found is higher than 0.05 and not seems to be 
significant when we evaluate the center of mass deviation 
that we measure with these two techniques makes us to have 
an impact in overall results. 
 
Conclusion: Determination of boost volume using pre-op 
tumor volume is not trustable in cases where tumor volume is 
not marked using clips during oncoplastic surgery of breast 
cancer and may result in geographical misses. 
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Purpose or Objective: To investigate the association 
between the molecular sub-types and the pattern of distant 
metastasis in carcinoma breast. 
 
Material and Methods: 400 patients of locally advanced 
breast carcinoma, without any distant metastasis, both 
clinically or by imaging were studied retrospectively.(Jan 
2010- Dec 2011) The ER/ PR and HER-2neu status of the 
patients was noted and the patients were classified into 
luminal A/B, Triple negative, Her2/neu enriched and 
Luminal/Her. 
All patients had received the treatment for carcinoma breast 
as per the standard protocols i.e. Cuarative treatment with 
surgery, Chemotherapy, and radiotherapy followed by 
hormonal therapy as per the indications. 
All the patients were followed up for local as well as distant 
failure and pattern of failure was co-related with the 
molecular subtypes. 
The major sites of distant metastasis were lungs, liver, bones 
and brain. 
molecular subtypes bone Liver Lungs brain local recurrence 
Luminal A/B 16/30  10/30 2/30 6/30 4/30 
Her 2 Neu enriched 28/66 30/66 20/66 20/56 18/56 
Luminal Her 16/28  11/28 2/28 8/28 6/28 
Triple Negative 7/19 6/19 7/19 4/19 0/19 
       
Results: Brain was the most common site of metastasis in Her 
2 /neu enriched subtype. 
Bone is the most common site of metastasis in all subtypes 
 
Conclusion: A strong association of different metastatic sites 
with the molecular status suggests vigilance about the 
symptoms (metastatic) beforehand. Organ specific metastasis 
may depend on the molecular subtype of the cancer. High 
rate of bone metastasis might be due to the role of bone 
marrow as a homing organ for the cancer cells. Early 
treatment of Her-2/ neu patients withTrastuzumab might 
reduce the rate of metastasis. Tailored strategies against 
distant metastasis concerning the molecular subtypes in 
breast cancer may be considered. 
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Purpose or Objective: Worldwide, breast cancer is the most 
common invasive cancer in women. The management of 
breast cancer depends on multiple factors. The purpose of 
this work is review the currently management of the axilla 
after neoadjuvant systemic therapy in breast cancer 
especially from the point of view of an oncology 
radiotherapist 
 
Material and Methods: In May 2015, we searched clinical trial 
registers, the Cochrane Central Register of Controlled Trials, 
Web of Science, EMBASE and MEDLINE and reviewed 
reference lists. Further hand searches were conducted of 
relevant journal proceedings. At the end, we principally 
reviewed both meta-analyses regarding the results of the SNB 
following NAC in patients with a diagnosis of clinically 
negative axillae, the results of NSABPB-18 and NSABP B-27 
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Trials, The ASCO recommendations about SNB, The Canadian 
SN FNAC and German SENTINA, The MD Anderson trials, and 
the ACOSOG Z 1071 and AO11202 ALLIANCE (NCTO 1901094) 
 
Results: For patients treated with NAC, patients with 
advanced stages (T3-4 /N2-3) should receive RT after 
independent NAC response. In early stages, it would be 
reasonable to receive treatment if there were residual 
disease; if doubts exist in cases of pRC, such cases should be 
assessed individually. It seems clear that patients with 
clinical regional involvement who present affectations of the 
lymph nodes following NAC will benefit from locoregional RT, 
but it is less clear in those who are pN0 following the NAC, as 
their risk of LRR is low.  
 
Conclusion: The benefit of locoregional RT is not clear in 
patients with pN0 following the NAC The ongoing NSABPB-51 
/RTOG1304 (NRG 9353) study has been designed to answer 
this question. We must wait for the results of this important 
trial. Until these results, we must follow the 
recommendations previously prescribed. 
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Purpose or Objective: To present the clinical results of ABPI 
using 3D-CRT and IG-IMRT following breast-conserving surgery 
(BCS) for early-stage breast cancer. 
 
Material and Methods: Between 2006 and 2014, 104 low risk 
breast cancer patients were treated with postoperative APBI 
given by means of 3D-CRT (n=44) using 3-5 non-coplanar, 
izocentric wedged fields, or IG-IMRT (n=60) technique using 
KVCBCT guidance for each fractions. The total dose of APBI 
was 36.9 Gy (9 x 4.1 Gy) using twice-a-day fractionation for 5 
consecutive days. Survival results, side effects, and cosmetic 
results were assessed. 
 
Results: At a median follow-up of 48 months (range: 25-112) 
one (0.9%) local recurrence was observed. Two patients 
(1.9%) died of internal disease. One (0.9%) contralateral 
recurrence and three (2.8%) secondary tumours were 
observed. Neither regional nor distant failure was detected. 
Acute side effects included grade 1 (G1) and G2 erythema in 
54 (51.9%) and 2 (1.9%), G1 parenchymal induration in 43 
(41.3%), G1 and G2 pain in 26 (25%) and 2 (1.9%) patients. No 
≥G3 or higher acute side effect occurred. Late side effects 
included G1 telangiectasia in 10 (9.6%) G1, G2, and G3 
fibrosis in 26 (25%), 3 (2.8%) and 1 (0.9%) patients 
respectively. Asymptomatic (G1) fat necrosis occurred in 8 
(7.7%) patients. The rate of excellent/good and fair/poor 
cosmetic results was 96 (92.3%), 8 (7.7%) respectively.  
 
Conclusion: Both 3D-CRT and IG-IMRT for delivery the ABPI is 
feasible and the 4 years clinical results and toxicity profile is 
comparable to other results using multicatheter APBI 
brachytherapy.  
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Purpose or Objective: Radiation and anthracyclines are 
known to induce cardiac damage. Despite the use of 3D 
planning the heart is still irradiated with non-negligible 
doses, therefore this problem needs further investigation. We 
perform an analysis of cardiac function in the left sided 
breast cancer survivors. Patients were treated with surgery 
alone (S), additional radiation (RT), additional anthracycline 
based chemotherapy (A) or both (RA).  
 
Material and Methods: A total of 140 patients were 
subjected to cardiological evaluation more than 8 years after 
primary treatment. We performed ECG and ECHO (in a part 
of patients we also had an ECG and ECHO performed before 
surgery), blood tests, chest X-ray. We also collected 
additional relevant information on patients (history, 
comorbidities, current treatment, etc.). Distribution of 
patients was as follows 50% RA arm, 18% S, 8% RT, 24% A. The 
mean time from the beginning of the treatment to 
examination was 12.2 years (8-15.9) in S, 11.7 (8-16.9) in A, 
10.7 (8-15.3) in RT, 10.1 (8.1-14.5) in RA. The majority of 
patients were treated with amputation (74%), the remaining 
with BCT. In chemotherapy arms 47% were treated with FAC, 
31% with CAF, 19% with AC, and 3% with TE. Hormonal 
treatment was given to 64% of patients, in the majority of 
them it was Tamoxifen-based. Radiotherapy dose varied 
between 50 and 70 Gy. 
 
Results: There was no significant difference in ejection 
fraction (EF) between the groups: median 56 (47-65) in S, 50 
(25-65) in A, 55 (47-62) in RT and 54 (35-67) in RA. Other 
evaluated parameters like size of the right and left ventricle, 
left atrium, thickness of septum and posterior wall also did 
not differ between groups. In the whole group in 21% of 
patients we observed chronic cardiac insufficiency. In 58% of 
patients there were other cardiovascular disorders as 
hypertension, hypercholesterolemia, atherosclerosis, 
arrhythmias, and valvular disorders. Only in one patient 
treated with radiation and chemotherapy we found impaired 
heart function without other additional causes.  
 
Conclusion: In the current series no unequivocal association 
between treatment regimen and long-term cardiac 
dysfunction could be found. Further studies in a well-
balanced patient population are needed to elucidate the 
impact of contemporary anthracycline-based systemic 
treatment and modern irradiation techniques on cardiac 
outcome.  
The research received funding from National Science Center 
Poland under grant no. N N 402 685640 
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Purpose or Objective: Incidental radiation dose to the heart 
and lung during left breast radiation therapy (RT) has been 
associated with an increased risk of cardiopulmonary 
morbidity especially in patients treated with antracyclin as 
neoadjuvant/adjuvant chemotherapy schedules after surgery. 
We conducted two different dosimetric analyses (by NTCP 
and Bio-DVH) to determine if left breast RT with the Active 
Breathing Coordinator (ABC) can reduce heart/left anterior 
descending artery (LAD) and lung dose without target 
coverage impairment. 
 
Material and Methods: Patients with stages 0-III left breast 
cancer (LBC) were enrolled and underwent simulation with 
both free breathing (FB) and ABC for comparison of 
dosimetry. ABC was used during the patient's RT course if the 
heart exposition was V(30) ≥ 12%. The prescription dose was 
50 Gy plus a boost in 88% and 2,75 Gy up to 44 Gy plus a 
boost in 22%. The primary endpoint was the magnitude of 
